IDEXX LABORATORIES INC /DE
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$44.34B
Cash Runway
4.8 mo
Lead Asset
—
Next Catalyst
—
Go deeper on IDEXX LABORATORIES INC /DE with Spotter
Ask follow-up questions and run a full multi-agent deep dive on IDXX — live, with citations.
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
4.8 months
D/E 1.18 · 1% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 31 sells (180d)
Key Financialsas of March 31, 2026
Cash
$200.5M
Quarterly Burn
$360.2M
Revenue
$1.14B
Free Cash Flow
$234.3M
Total Liabilities
$1.83B
Shareholders Equity
$1.56B
Current Ratio
1.12
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Commercialization & Governance
Commercialization
- Launch Markets
- -
- Commercial Strategy
- IDEXX markets and sells products worldwide through direct sales forces, independent distributors, and other resellers. The company maintains a sales presence in the U.S. and major regions worldwide including Africa, Asia Pacific, Canada, Europe, and Latin America. Distribution channels are selected based on product type, technical service requirements, customer concentration, and regulatory requirements. Companion animal diagnostic products are marketed directly to veterinarians in the U.S., and through direct sales and distributors outside the U.S. Water and LPD products are marketed primarily through direct sales in the U.S. and Canada, and through direct sales and selected distributors outside these regions.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,303
Total value held
$40.38B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 10,365,014 | $5.82B |
| blackrock, inc. | 8,365,553 | $4.70B |
| vanguard portfolio management llc | 3,910,863 | $2.20B |
| state street corp | 3,674,185 | $2.06B |
| geode capital management, llc | 2,660,999 | $1.50B |
| bamco inc /ny/ | 1,633,367 | $917.8M |
| bank of new york mellon corp | 1,504,532 | $845.4M |
| morgan stanley | 1,315,954 | $739.4M |
| blair william & co/il | 946,336 | $531.7M |
| northern trust corp | 911,893 | $512.4M |
Showing top 10 of 1,303 institutional holders of IDEXX LABORATORIES INC /DE. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
Who is the CEO of IDEXX LABORATORIES INC /DE?
Mr. Michael G. Erickson Ph.D. is the chief executive officer of IDEXX LABORATORIES INC /DE (IDXX).
Where is IDEXX LABORATORIES INC /DE headquartered?
IDEXX LABORATORIES INC /DE (IDXX) is headquartered in Westbrook, ME, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on IDEXX LABORATORIES INC /DE
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.